COSSA, LUCA GIULIO
 Distribuzione geografica
Continente #
EU - Europa 900
NA - Nord America 428
AS - Asia 133
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.478
Nazione #
US - Stati Uniti d'America 427
IT - Italia 361
IE - Irlanda 290
SE - Svezia 90
UA - Ucraina 70
CN - Cina 56
DE - Germania 33
SG - Singapore 27
IN - India 24
HK - Hong Kong 21
CZ - Repubblica Ceca 18
SN - Senegal 15
FI - Finlandia 14
BE - Belgio 6
GB - Regno Unito 6
BG - Bulgaria 3
FR - Francia 3
IR - Iran 2
JP - Giappone 2
RU - Federazione Russa 2
BO - Bolivia 1
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
NL - Olanda 1
Totale 1.478
Città #
Lecce 298
Dublin 290
Chandler 78
New York 35
Jacksonville 34
Wayanad 23
Munich 22
Brno 18
Hong Kong 18
Kent 18
Princeton 17
Ann Arbor 16
Dakar 15
Singapore 14
Des Moines 11
Lequile 10
Bari 8
Copertino 7
Ogden 7
Brussels 6
Falls Church 6
West Jordan 6
Wilmington 6
Seelze 5
Jinan 4
Norwalk 4
San Mateo 4
Boardman 3
Central District 3
Florence 3
Helsinki 3
Lanzhou 3
Leawood 3
Monopoli 3
San Pietro Vernotico 3
Sofia 3
Taiyuan 3
Aradeo 2
Bremen 2
Brooklyn 2
Hangzhou 2
Taizhou 2
Taranto 2
Tokyo 2
Zhengzhou 2
Amsterdam 1
Ardabil 1
Ashburn 1
Athens 1
Augusta 1
Chicago 1
Cochabamba 1
Dallas 1
Denver 1
Foggia 1
Frankfurt am Main 1
Hanover 1
Lappeenranta 1
London 1
Los Angeles 1
Madrid 1
Milan 1
Monmouth Junction 1
Mumbai 1
Nanchang 1
Nanjing 1
Ningbo 1
Novokuznetsk 1
Padova 1
Pavia 1
Puxian 1
Shanghai 1
Shenyang 1
Tel Aviv 1
Tianjin 1
Toronto 1
Villa Castelli 1
Zurich 1
Totale 1.059
Nome #
Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway 110
ADP sensitizes ZL55 cells to the activity of cisplatin 100
Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma 95
In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma 92
ADP sensitizes ZL55 cells to the activity of anticancer cisplatin 91
[Pt(O,O′-acac)(γ-acac)(DMS)] inhibits malignant pleural mesothelioma cells in vitro and in vivo 89
Cytotoxic effects of [ Pt( O,O' – acac)(γ-acac)(DMS)] and cisplatin in Caki-1 renal cancer cells 87
[Pt(O,O'-acac)(γ-acac)(DMS)] induces autophagy and apoptosis in Skov-3 ovarian carcinoma cells 86
[Pt(O,O'-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells 86
Purinergic receptors in a pleural mesotelioma cell line. 81
New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies 80
PKC-δ/PKC-α activity balance regulates the lethal effects of cisplatin 79
Protein kinase C-delta mediates cisplatin-induced apoptosis of ZL55 mesothelioma cells 78
Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture. 77
TGF-β1 activates RSC96 Schwann cells migration and invasion through MMP-2 and MMP-9 activities 76
[Pt(O,O'-acac)(γ-acac)(DMS)] alters SH-SY5Y cell migration and invasion by the inhibition of Na+/H+ exchanger isoform 1 occurring through a PKC-ε/ERK/mTOR Pathway. 71
Bradykinin stimulates prostaglandin E2 release in human skeletal muscular fibroblasts 71
Evaluation of the Antitumor Effects of Platinum-Based [Pt(η1-C2H4-OR)(DMSO)(phen)]+ (R = Me, Et) Cationic Organometallic Complexes on Chemoresistant Pancreatic Cancer Cell Lines 43
Immunolocalization of the AT-1R Ang II Receptor in Human Kidney Cancer 28
Blood Metabolite Profiling of Antarctic Expedition Members: An 1H NMR Spectroscopy-Based Study 20
Totale 1.540
Categoria #
all - tutte 8.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.670


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020152 0 0 0 15 12 49 21 25 7 3 20 0
2020/2021200 18 7 21 35 18 17 1 18 7 18 23 17
2021/2022122 2 1 3 23 13 8 4 5 5 12 15 31
2022/2023555 20 52 27 19 23 40 4 29 314 1 19 7
2023/2024310 16 23 16 24 28 39 1 16 32 39 53 23
2024/202560 25 5 29 1 0 0 0 0 0 0 0 0
Totale 1.540